Coccidioidomycosis: Difference between revisions
No edit summary |
|||
| Line 46: | Line 46: | ||
*[[TB]] | *[[TB]] | ||
==Workup== | ==Diagnosis== | ||
===Workup=== | |||
*Basic workup | *Basic workup | ||
**Typically normal WBC count or mild lymphocytosis, monocytosis, and/or eosinophilia (>5%) | **Typically normal WBC count or mild lymphocytosis, monocytosis, and/or eosinophilia (>5%) | ||
| Line 58: | Line 59: | ||
**Skin testing | **Skin testing | ||
== | ==Management== | ||
*Often self-limited mild disease not requiring treatment | *Often self-limited mild disease not requiring treatment | ||
*[[Azoles]] first line | *[[Azoles]] first line | ||
| Line 68: | Line 69: | ||
**Lipid formulations of amphotericin B - 2-5 mg/kg/day IV | **Lipid formulations of amphotericin B - 2-5 mg/kg/day IV | ||
== | ==Disposition== | ||
* | |||
==See Also== | |||
* | |||
==References== | |||
<References/> | |||
[[Category:ID]] | [[Category:ID]] | ||
Revision as of 07:38, 18 August 2015
Background
- Fungal infection caused by Coccidioides immitis and C posadasii
- Organisms found in soil in arid climates of southwestern US and nearby areas
- Transmitted by inhalation of airborne spores
- Also known as Valley Fever
Clinical Features
- Often asymptomatic
- Most commonly affects lungs
- Mild ILI 1-4 weeks after exposure
- Fever
- Sore throat
- Cough
- Headache
- Fatigue
- Pleuritic chest pain
- More severe presentation
- Rarely, respiratory failure
- Disseminated disease, more common in immunosuppressed
- Dramatic sweats
- Dyspnea at rest
- Fever
- Weight loss
- 50% develop meningitis
Differential Diagnosis
- Acute respiratory distress syndrome
- Blastomycosis
- Enteropathic arthropathies
- Eosinophilic pneumonia
- Histoplasmosis
- Lung abscess
- Lung cancer
- Lymphoma
- Myelophthisic anemia
- Old granuloma
- Paracoccidioidomycosis
- Pericarditis (acute or chronic)
- Pneumocystis jiroveci pneumonia
- Sarcoidosis
- Solitary pulmonary nodule
- TB
Diagnosis
Workup
- Basic workup
- Typically normal WBC count or mild lymphocytosis, monocytosis, and/or eosinophilia (>5%)
- Elevated ESR
- CXR
- LP if suspect meningitis
- Special testing
- Immunoglobulin testing
- Culture
- PCR testing
- Skin testing
Management
- Often self-limited mild disease not requiring treatment
- Azoles first line
- Treatment options
- Itraconazole - 200 mg 2-3 times/day orally
- Fluconazole - 400-800 mg/day orally or IV
- Ketoconazole - 400 mg/day orally
- Amphotericin B deoxycholate - 0.5-1.5 mg/kg/day IV
- Lipid formulations of amphotericin B - 2-5 mg/kg/day IV